Medarex, Inc. announced today that preclinical data from several investigational antibody-drug conjugate candidates in development, demonstrated enhanced anti-tumor activity
PRINCETON, N.J., USA | April 16, 2008 | Medarex, Inc. (Nasdaq: MEDX) announced today that preclinical data from several investigational antibody-drug conjugate candidates in development, each in separate studies, demonstrated enhanced anti-tumor activity in xenograft models when compared to the anti-cancer antibodies alone. The use of antibody- drug conjugate candidates is another new strategy to fight cancer by targeting molecules implicated in disease (including B7-H4, prostate-specific membrane antigen, mindin/RG1, CD70 and Ptk7) with antibodies linked to cytotoxic agents that are designed to kill cancer cells. Results from the preclinical studies were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.
"Our research and expertise in the antibody field continues to broaden our pipeline with potentially important anti-cancer agents," said Howard H. Pien, President and CEO of Medarex. "We are encouraged by the single-dose efficacy observed in animal models from our antibody-drug conjugate technology platform, and remain on track to prepare for our first antibody-drug conjugate candidate IND filing this year."
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
SOURCE: Medarex, Inc.
Post Views: 173
Medarex, Inc. announced today that preclinical data from several investigational antibody-drug conjugate candidates in development, demonstrated enhanced anti-tumor activity
PRINCETON, N.J., USA | April 16, 2008 | Medarex, Inc. (Nasdaq: MEDX) announced today that preclinical data from several investigational antibody-drug conjugate candidates in development, each in separate studies, demonstrated enhanced anti-tumor activity in xenograft models when compared to the anti-cancer antibodies alone. The use of antibody- drug conjugate candidates is another new strategy to fight cancer by targeting molecules implicated in disease (including B7-H4, prostate-specific membrane antigen, mindin/RG1, CD70 and Ptk7) with antibodies linked to cytotoxic agents that are designed to kill cancer cells. Results from the preclinical studies were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.
"Our research and expertise in the antibody field continues to broaden our pipeline with potentially important anti-cancer agents," said Howard H. Pien, President and CEO of Medarex. "We are encouraged by the single-dose efficacy observed in animal models from our antibody-drug conjugate technology platform, and remain on track to prepare for our first antibody-drug conjugate candidate IND filing this year."
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
SOURCE: Medarex, Inc.
Post Views: 173
